Plasma Protease C1-Inhibitor Market Report 2026

Plasma Protease C1-Inhibitor Market Overview

• Plasma Protease C1-Inhibitor market size has reached to $3.85 billion in 2025 • Expected to grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Growing Investment In Rare Diseases Fueling The Growth Of The Market Due To Rising Demand For Targeted Therapies And Regulatory Incentives • Market Trend: Advancements In C1-Inhibitor Therapies Driven By Need For Faster And Safer Hae Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Plasma Protease C1-Inhibitor Market?

Plasma protease C1-inhibitors are drugs that inhibit the activity of plasma protease C1 in the complement system. Their primary purpose is to regulate immune responses by preventing excessive activation of the complement cascade and controlling inflammation. They help maintain balance in immune and coagulation pathways to protect tissues from damage. The main types of drugs that target plasma protease C1-inhibitor are C1-inhibitors, C1-esterase inhibitors, recombinant inhibitors, kallikrein inhibitors, and selective bradykinin B2 receptor antagonists. C1-inhibitors are blood proteins that regulate the complement system, a component of the immune system responsible for defending against infections and inflammation. These drugs are typically available in lyophilized and injectable dosage forms and distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Plasma Protease C1-Inhibitor Market Growth Forecast?

The plasma protease c1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to increasing development of next-generation inhibitors, rising demand for self-administered therapies, expansion of rare disease treatment programs, growing investment in recombinant biologics, increasing focus on long-term disease control. Major trends in the forecast period include increasing adoption of recombinant c1-inhibitors, rising demand for plasma-derived therapies, growing focus on rare disease management, expansion of subcutaneous administration options, enhanced emphasis on treatment safety and efficacy.

Global Plasma Protease C1-Inhibitor Market Segmentation

1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist 2) By Dosage Form: Lyphophlised, Injectables 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor 2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor 3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor 4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor 5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist

What Is The Driver Of The Plasma Protease C1-Inhibitor Market?

The growing investment in rare diseases is expected to propel the growth of the plasma protease C1-inhibitor market going forward. A rare disease is a health condition that affects a small percentage of the population, typically fewer than 1 in 2,000 people. These conditions are often chronic and progressive and can be life-threatening or disabling. Investment in rare diseases is primarily due to the growing recognition of unmet medical needs and the potential for high returns through regulatory incentives such as orphan drug designation, market exclusivity, and reduced development costs. Investment in rare diseases drives the development of plasma protease C1-inhibitors by funding research and innovation to address hereditary angioedema and other rare conditions where C1-inhibitor deficiencies cause severe symptoms, thus accelerating the availability of targeted therapies. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, marking a 307% increase compared to the $1.8 billion raised in the same period in 2023. Therefore, the growing investment in rare diseases is driving the growth of the plasma protease C1-inhibitor industry.

Key Players In The Global Plasma Protease C1-Inhibitor Market

Major companies operating in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Octapharma AG, Ionis Pharmaceuticals Inc, Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc, Pharming Group NV, KalVista Pharmaceuticals Inc, Pharvaris NV, Lev Pharmaceuticals, Shire Pharmaceuticals, Dyax Corp, Intellia Therapeutics Inc, Alnylam Pharmaceuticals Inc, Moderna Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Protalix BioTherapeutics Inc, Apellis Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, UCB SA, Pfizer Inc

Global Plasma Protease C1-Inhibitor Market Trends and Insights

Major companies operating in the plasma protease C1-inhibitor market are focusing on developing innovative solutions, such as recombinant and plasma-derived C1-inhibitors, to prevent and treat hereditary angioedema (HAE) attacks, providing faster symptom control and improved safety compared with older therapies that had limited availability or slower onset. C1-inhibitors are proteins that regulate the complement system, controlling excessive bradykinin production and reducing the severity of HAE-related swelling episodes. For instance, in January 2023, Takeda Biopharmaceuticals India Private Limited, an India-based pharmaceutical company, launched Cinryze in India, its first approved C1-inhibitor therapy for hereditary angioedema. Cinryze is a plasma-derived C1-inhibitor administered intravenously that functions by replacing deficient or dysfunctional C1-inhibitor protein and helps prevent recurrent HAE attacks; unique features include high purity, proven efficacy in prophylaxis, and a favorable safety profile; applications span long-term prophylaxis in adults and adolescents with HAE; benefits include reduced frequency and severity of angioedema attacks, improved quality of life, and accessible therapy for patients in India.

What Are Latest Mergers And Acquisitions In The Plasma Protease C1-Inhibitor Market?

In December 2023, Danaher Corporation, a US-based conglomerate company, acquired Abcam plc for $5.7 billion. With this acquisition, Danaher aims to strengthen its life sciences portfolio by enhancing its protein research tools and accelerating innovation in disease mapping and drug discovery. Abcam Plc is a UK-based biotechnology company that offers several products related to plasma protease C1-inhibitor.

Regional Outlook

North America was the largest region in the plasma protease C1-inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Plasma Protease C1-Inhibitor Market?

The plasma protease C1-inhibitor market consists of sales of berinert, cinryze, haegarda, firazyr, and lcatibant. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Plasma Protease C1-Inhibitor Market Report 2026?

The plasma protease c1-inhibitor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the plasma protease c1-inhibitor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.